| 摘要 |
<p>The present invention relates to therapeutic combinations comprising (2R, cis) -4-amino-1- (2-hydroxymethyl-1, 3-oxathiolan-5-yl) -pyrimidin-2-one (lamivudine) and a second therapeutic agent selected from (9-[(R) -2-(phosphonomethoxy) ethyl]adenine, (PMEA or adefovir) and bis(pivaloyloxymethyl) (9-[(R) -2- (phosphonomethoxy)ethyl]adenine, (the oral prodrug of PMEA, adefovir dipivoxil) w hich have anti-hepatitis B virus (HBV) activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HBV infections including infections with HBV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.</p> |
